No Data
No Data
Newamsterdam Pharma Co Insider Sold Shares Worth $707,400, According to a Recent SEC Filing
NewAmsterdam Pharma Price Target Maintained With a $37.00/Share by Piper Sandler
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Piper Sandler analyst Yasmeen Rahimi maintains $NewAmsterdam Pharma(NAMS.US)$ with a buy rating, and maintains the target price at $37.According to TipRanks data, the analyst has a success rate of 39.
Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
While Institutions Own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), Private Equity Firms Are Its Largest Shareholders With 47% Ownership
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)